目的：了解某院多重耐药菌的临床分布特点，以采取针对性的预防控制措施。方法回顾性分析该院2012年1月1日-12月31日检出的891株多重耐药菌监测资料。结果891株多重耐药菌中，以产超广谱β-内酰胺酶（ESBLs）的大肠埃希菌居首位（342株，38．39％），其次为产ESBLs肺炎克雷伯菌（195株，21．89％）、多重耐药鲍曼不动杆菌（185株，20．76％）、耐甲氧西林金黄色葡萄球菌（138株，15．49％）、多重耐药铜绿假单胞菌（27株，3．03％）、产ESBLs奇异变形杆菌（2株，0．22％）、产ESBLs产酸克雷伯菌（2株，0．22％）；主要集中在综合重症监护室（ICU；163株，18．29％）、神经内科（136株，15．26％）、普通外科（103株，11．56％）、神经外科（85株，9．54％）和呼吸内科（71株，7．97％）。痰标本分离多重耐药菌最多的是多重耐药鲍曼不动杆菌（242株，50．63％），主要集中在综合ICU；尿标本分离最多的是产ESBLs大肠埃希菌（141株，80．57％），主要集中在神经内科和泌尿外科。结论该院多重耐药菌感染部位主要为下呼吸道和泌尿系统；应加强对高危科室和易感人群的监控，制定有针对性的预防控制措施，遏制多重耐药菌的感染和传播。%Objective To realize the characteristics of clinical distribution of multidrug-resistant organisms (MDRO)in a hospital,and take specific measures for the prevention and control of infection.Methods Surveillance data of 891 MDR isolates detected in a hospital between January 1 and December 31,2012 were analyzed retrospec-tively.Results Of 891 MDR isolates,extended-spectrumβ-lactamase (ESBL)-producing Escherichiacoli ranked first(342,38.39% ),followed by ESBL-producing Klebsiellapneumoniae(195,21.89% ),MDRAcinetobacterbau-mannii(185,20.76% ),methicillin-resistantStaphylococcusaureus(138,15.49% ),MDRPseudomonasaeruginosa (27,3.03% ),ESBL-producingProteusmirabilis(2,0.22% ),and ESBL-producing Klebsiellaoxytoca(2,0.22% );Bacteria mainly concentrated on general intensive care unit(ICU)(163,18.29% ),department of neurology(136, 15.26% ),general surgery(103,11.56% ),neurosurgery(85,9.54% ),and respiratory diseases department(71, 7.97% ).The most common bacteria isolated from sputum was MDR Acinetobacterbaumannii(242,50.63% ),and mainly concentrated on general ICU;the most common bacteria isolated from urine was ESBL-producing Escherich-iacoli(141 ,80.57% ),mainly concentrated on the departments of neurology and urology. Conclusion MDRO infec-tion in this hospital mainly concentrate on lower respiratory tract and urinary system. Monitor on high-risk depart-ments and vulnerable patients should be intensified,targeted preventive measures should be stressed to curb MDRO infection and spread.
展开▼
